PRTX-100
Identification
- Generic Name
- PRTX-100
- DrugBank Accession Number
- DB05947
- Background
PRTX-100 is a highly-purified form of Staphylococcal Protein A that binds directly to monocytes and a subset of B-cells that are involved in the development and progression of various autoimmune diseases. These binding interactions enable the compound to modulate the function of these cells and restore the balance of the immune system.
- Type
- Small Molecule
- Groups
- Investigational
- Synonyms
- PRTX 100
- PRTX100
- Staphylococcus aureus protein A
Pharmacology
- Indication
Investigated for use/treatment in autoimmune diseases, inflammatory disorders (unspecified), rheumatoid arthritis, and thrombocytopenia.
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API
- Pharmacodynamics
Not Available
- Mechanism of action
PRTX-100 aims to restore normal immune system function by selectively modulating only the B-cells that are producing pathogenic auto-antibodies, which play a role in the induction and maintenance of autoimmune diseases. PRTX-100 achieves this specificity due to its ability to bind to immunoglobulins that are of a specific lineage, namely VH3, which is also the lineage that is most prevalent in the auto-antibodies that are present in numerous autoimmune diseases.
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Not Available
- Classification
- Not classified
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- Not Available
- CAS number
- Not Available
- InChI Key
- Not Available
- InChI
- Not Available
- IUPAC Name
- Not Available
- SMILES
- Not Available
References
- General References
- Not Available
- External Links
- Not Available
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 1 Completed Treatment Healthy Volunteers (HV) 1 1 Completed Treatment Rheumatoid Arthritis 1 1 Terminated Treatment Immune Thrombocytopenia (ITP) 1 1, 2 Completed Treatment Rheumatoid Arthritis 1 1, 2 Terminated Treatment Immune Thrombocytopenia (ITP) 2
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
- Not Available
- Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at November 18, 2007 18:28 / Updated at July 18, 2023 22:56